论文信息 - Predictive value of β2-microglobulin (β2-m) levels in chronic lymphocytic leukemia since Binet A stages

Predictive value of β2-microglobulin (β2-m) levels in chronic lymphocytic leukemia since Binet A stages

We read with interest the study by Rossi and coworkers, reporting CD49d expression as risk factor of treatment free survival (TFS) in Binet A CLL patients.[1][1] In this paper, a close association between CD49d and CD38, LDH and β2-m is also described. We would like to add further information about

[1] M. Hurme,et al. Induction of beta-2-microglobulin release in vitro by chronic lymphocytic leukaemia cells: relation to total protein synthesis. , 1999, Leukemia research.

[2] D. Rossi,et al. CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia , 2008, Haematologica.

[3] R. Foà,et al. New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia , 2005, Current opinion in oncology.

[4] Kim-Anh Do,et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. , 2007, Blood.

[5] G. Capelli,et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. , 2001, Blood.

[6] K. Nilsson,et al. Beta 2-microglobulin in chronic lymphocytic leukaemia. , 2009, Scandinavian journal of haematology.